JW PharmaceuticalJW중외제약
001060 · KOSPI · ₩001060 · JW중외제약
₩23,150▲ ₩50 (0.22%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩775B | ₩719B | ₩749B | ₩684B | ₩607B |
| Cost of sales | ₩416B | ₩396B | ₩413B | ₩396B | ₩372B |
| Gross profit | ₩359B | ₩323B | ₩336B | ₩288B | ₩234B |
| Operating income | ₩94B | ₩82B | ₩100B | ₩63B | ₩31B |
| Net income | ₩62B | ₩65B | ₩38B | ₩30B | −₩1.4B |
| Net income to shareholders | ₩62B | ₩65B | ₩37B | ₩32B | −₩968M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩605B | ₩605B | ₩645B | ₩628B | ₩633B |
| Current assets | ₩297B | ₩306B | ₩378B | ₩425B | ₩366B |
| Cash and equivalents | ₩39B | ₩10B | ₩16B | ₩34B | ₩33B |
| Total liabilities | ₩236B | ₩275B | ₩380B | ₩402B | ₩445B |
| Current liabilities | ₩209B | ₩209B | ₩287B | ₩380B | ₩283B |
| Borrowings | ₩32B | ₩67B | ₩30B | — | — |
| Total equity | ₩369B | ₩329B | ₩265B | ₩226B | ₩189B |
| Shareholders' equity | ₩369B | ₩329B | ₩265B | ₩226B | ₩189B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩96B | ₩79B | ₩87B | ₩57B | ₩18B |
| Capital spending | ₩12B | ₩8.3B | ₩27B | ₩9.9B | ₩7.5B |
| Free cash flow | ₩85B | ₩71B | ₩60B | ₩47B | ₩11B |
| Dividends paid | ₩11B | ₩9.7B | −₩8.8B | ₩7.4B | ₩7.1B |
Consolidated where available. Amounts in won.
Also known as: JW Pharmaceutical / JW중외제약 / 001060 / KRX:001060
Source: KRX statistical information